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Abstract 
 
Chronic or episodic severe itch is recurrent in atopic dermatitis (AD). Non-histaminergic neuronal itch 
pathways are suggested to dominate in AD itch, contributing to an “itch-scratch-itch cycle” that prolongs 
and worsens itch, pain, and skin lesions. We hypothesized that non-histaminergic neuronal sensitization 
contributes to itch in AD. Hence, we compared sensitivity to thermal, mechanical, and chemical pruritic 
stimuli in AD patients and controls. The study comprised 25 AD patients with chronic itch and 25 healthy 
controls. Questionnaires on itch characteristics were administered, and sensory tests were conducted intra-
lesionally, extra-lesionally, and in homologous areas of controls. Thermal and mechanical quantitative 
sensory testing (QST) as well as histamine and cowhage provocations were performed. Subsequently, 
hyperknesis and vasomotor reactivity were assessed. Average itch and associated pain among AD patients 
were 60.7±4.3 and 39.7±5.2 (VAS0-100), respectively. Patients experienced significantly higher itch from 
cowhage both intra- and extra-lesionally compared to controls, whereas histamine-evoked itch intensity 
was not significantly different between groups. No gr up differences were found for thermal QSTs or 
pain evoked by itch provocations. Patients had decreased mechanical detection thresholds intra-lesionally 
and increased mechanical pain sensitivity intra- and extra-lesionally. Lastly, patients exhibited intra- and 
extra-lesional hyperknesis prior to chemical itch provocations and augmented hyperknesis following itch 
provocations. Increased itch to a non-histaminergic pruritogen (but not histamine) suggests pathway-
specific itch sensitization in AD while increased susceptibility to mechanically-evoked itch and pain, 
particularly intra-lesionally, suggests sensitization of normally non-pruritic mechano-sensitive circutry. 
Drugs targeting the non-histaminergic (PAR2/TRPA1+) itch-pathway and itch sensitization are promising 
for treating AD itch. 
 
 
1. Introduction 
 
Atopic dermatitis is a chronic pruritic inflammatory skin condition characterized by lesions with 
erythema, exudation, excoriations, lichenification, a d xerosis as well as chronic or episodic itch and
cutaneous pain.18,25,33,86,90 The disease is common, can be debilitating for affected patients, and is often 
difficult to treat adequately.68,90 Pathoetiologically, AD is associated with genetic, immunological, 
environmental and skin barrier factors.32,86 Recently, neuronal sensitization has also been proposed as a 
disease contributor.41,87,97 Knowledge on the neurophysiological basis of itch has been greatly expanded in 
the last decade as parallel peripheral pathways of itch transduction have been discovered and 
explored.6,45,60,84 In humans, the two most well studied pathways of itch rely on mechano-insensitive C-
fibers (CMi) transmitting histaminergic itch and polymodal C-fibers (PmC) transmitting non-
histaminergic itch.36,45,60 To a certain extent, these fibers express different molecular transducers 
important for itch signaling; e.g., CMi fibers express histamine receptor 1 and PmC fibers express 
proteinase-activated receptor-2 (PAR2), which tryptase and mucunain activate to induce itch.31,39 
 
It is well established that following acute pain as well as in inflammatory and neuropathic pain 
conditions, peripheral nociceptors may exhibit increased sensitivity to various stimuli. At the same time, 
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the spinal processing of these nociceptive signals c n be facilitated or disinhibited.15,53,56,77 These 
processes are proposed to contribute to the aggravation and chronification of pain in patients and mediate 
clinical epiphenomenona such as hyperalgesia and allo ynia to mechanical and thermal stimuli.77,94 It is 
currently unknown whether similar processes contribu e to increasing itch severity in patients suffering 
from chronic inflammatory itch conditions, such as AD. The indirect evidence of neuronal sensitization in 
AD includes: 1) sustained itch after resolution of active lesions,17 2) itch in response to normally 
innocuous mechanical stimuli (such as certain fabrics),40,92 3) poor correlation between objective disease 
severity (e.g., SCORAD) and itch intensity,23 and 4) case-based indications of an antipruritic effect of 
centrally acting anti-hyperalgesic drugs,71 and 5) altered expression of molecular transducers on 
peptidergic cutaneous fibers.83 
 
Neuronal sensitization to histamine-induced itch and skin reactivity in AD have been studied 
extensively.68,83,91,92 Generally, itch in response to histamine provocatin is unchanged or even decreased 
in non-lesional AD skin versus healthy skin, and varying results have been derived from intra-lesional 
histamine provocations in AD.5,38,41–43,48,67,91 This is consistent with the fact that antihistamine treatment 
has little or no effect on clinical itch severity in AD and thus histaminergic signaling is considered to have 
little implication on the pathophysiology.68,90,93  
 
Recently, a non-histaminergic model of itch, relying on the naturally occurring PAR2 agonist, mucunain 
from the cowhage plant, has been re-introduced. This type of evoked itch is entirely resistant to 
antihistamines45,60 and evokes mild nociceptive sensations akin to those associated with itch in AD.52,79 
Accordingly, it has been suggested that this model may much more accurately mimic itch in AD and other 
conditions than the rigorously studied histaminergic models of itch.34,59,67 
 
The aim of this study was to compare sensory sensitivity o pruritic chemical, thermal, and mechanical 
stimuli between AD patients with chronic itch and healthy controls (HCs), investigating both lesional and 
non-lesional skin areas.  
 
2. Methods 
 
2.1. Participants 
Study subjects comprised 25 patients with AD (25.2±0 9 years, 10M/15F) and 25 healthy age- and 
gender-matched volunteers (26.3±1.3 years 14M/11F). All AD patients fulfilled the diagnostic criteria of 
the UK Working Party and were initially diagnosed by a dermatologist. Patients were only included if 
they presented chronically (>6 weeks82) pruritic atopic dermatitis with mean daily itch rated above 3 
(NRS0-10), lesions manifesting on the upper extremities, and  eczema-free skin area also on the upper 
extremities. Use of antihistamines was discontinued 48 hours prior to the experiment and all topical 
agents and emollients were discontinued 24 hours prior to the experiment. To enable the study of 
neuronal sensitization in patients with chronically itchy, treatment-resistant AD in situ, patients were 
instructed to continue their usual treatment regimen uninterrupted, with the exceptions stated above. Prior 
to enrollment, all participants were explicitly informed, verbally and in writing, that they were free to 
withdraw from the study at any time and that any procedure they deemed intolerable would be ceased 
immediately.  
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2.2. Study procedure 
All subjects provided written informed consent prior t  experimental procedures, and the regional ethics 
committee approved the study (N-20150058). Fig. 1 provides an overview of the conducted experimental 
procedures. Prior to the experimental session, AD patients were evaluated using Scoring Atopic 
Dermatitis (SCORAD)1,46 and completed a Danish version of the Eppendorfer Itch Questionnaire23 as 
well as the adapted Danish Itch Severity Scale questionnaire99 (initially developed by Yosipovitch et al. 
(2001)98, deriving descriptors from the McGill Pain Questionnaire). Thereafter, two 4 x 4 cm square areas 
were marked on the upper extremities: one in a representative atopic lesion and one in an area of eczema-
free skin. Scabbed and significantly exudative and lichenificated lesions were avoided; if not possible, an 
area in the margin of such lesions was used. The anatomical locations of these areas were mirrored in the 
HC group. All experimental procedures were subsequently conducted within these two areas (with the 
order of lesional vs. non-lesional being randomized) following the sequence outlined in Fig. 1. For all 
outcomes, comparisons were made between lesion/non-lesional sites in AD and to anatomically 
corresponding control areas in HCs. All sessions were conducted in the same temperature-controlled 
laboratory at ~21-22 °C. AD patients and healthy controls were enrolled and tested in parallel to avoid 
potential seasonal biases55.  
 
2.3. Quantitative sensory testing (QST) 
The applied QST protocol was partly derived from the guidelines of the German Research Network on 
Neuropathic Pain (DFNS).73 The verbal instructions (in Danish) for participants from the DFNS protocol 
were derived from the supplementary materials of Olsen et al. (2014).65 
 
2.3.1. Thermal detection and pain thresholds: Tests for cold detection threshold (CDT), warmth 
detection threshold (WDT), cold pain threshold (CPT), and heat pain threshold (HPT) were performed 
using a Medoc Pathway (Medoc Ltd, Ramat Yishay, Israel) equipped with a 3 × 3 cm advanced thermal 
stimulator probe with a baseline temperature of 32°C. Ramping stimuli of 1°C/s were delivered until the 
subjects identified the associated threshold (first perception of cold or warmth and first perception of 
cold- or heat-induced pain) by pressing a button. Thereafter the temperature of the probe returned to the 
baseline temperature at a rate of 5°C/s. The results were calculated as the arithmetic mean of the 
thresholds from three repeated ramps. 
  
2.3.2. Mechanical detection, pain threshold, and sensitivity: To determine the mechanical detection 
threshold (MDT), a set of 20 calibrated Von Frey filaments (North Coast Medical, Gilroy, CA, USA) 
with exerted forces ranging from 0.078 mN to 2.9 N was applied over five ascending/descending series of 
stimuli. The subjects were asked to report upon any sensation from the area. The final MDT was 
calculated as the mean of the values obtained in each of the five series of stimuli. The mechanical pain 
threshold (MPT) was evaluated using a set of seven w ight-calibrated pinprick stimulators (MRC 
Systems, Germany) with weights from 8 to 512 mN (Log2). During five ascending/descending series of 
stimuli, the subjects reported when a perception of ‘sharpness’ or ‘pricking pain’ was first sensed. The 
final MPT was calculated as the mean of the values obtained in the five series of stimuli. The mechanic l 
pain sensitivity (MPS) was assessed to detect pinprick hyperalgesia to suprathreshold stimulation. The 
seven pinprick stimuli were applied in ascending order, and the subject was instructed to rate pain 
intensity of each stimulus on a numerical rating scale (NRS0–10, 0 = no pain, 10 = worst imaginable pain) 
allowing the use of decimals. The final MPS was calcul ted as the arithmetic mean of two consecutive 
series. Wind-up ratio (WUR) was assessed using the pinprick stimulator one intensity above the 
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individual average MPT. The subjects were asked to rate the pain intensity following a single stimulus 
and thereafter the last of a subsequent series of 10 consecutive stimuli (1 stimulus/second). This 
procedure was repeated twice, and a mean ratio was calculated.  
 
2.4. Chemically provoked itch 
 
2.4.1. Itch induction: Two types of itch provocations were conducted. Histaminergic itch was evoked 
using intra-epidermal punctures of 1% histamine hydrochloride with standard 1mm skin prick test (SPT) 
lancets (Allergopharma, Hamburg, Germany). A drop of histamine solution was placed in the 
predetermined area and an SPT lancet was pricked throug  the histamine into the epidermis using a 120 g 
weight-calibrated device (Aalborg University, Denmark) for 1–2 seconds.9,13 Non-histaminergic itch was 
induced using cowhage spicules, which contain the PAR2 agonist mucunain. The spicules were prepared 
immediately before administration under a stereomicros ope (Seben Incognita microscope, Seben GmbH, 
Berlin, Germany) using a negative grip tweezer (Electron Microscopy Science, Dumont, Switzerland). 
Approximately 45 spicules were applied to the skin and gently rubbed with the experimenter’s fingertip 
for 15-20 seconds to ensure insertion (the delivered volume of mucunain using this method has been 
calculated to 15–30 ng).67 Histamine solution and cowhage spicules were stored at 4 °C between sessions 
but always taken out well in advance of experiments a d applied when at room temperature. Both of these 
human surrogate itch models have previously been utilized and found to be reliable.6,13 
 
2.4.2. Assessment of evoked itch and pain: Intensity of itch and pain was assessed using two visual 
analogue scales (VAS), one for each sensory quality, following each itch provocation. Two computerized 
100-mm VAS ranging from 0 to 100 (eVAS Software, Aalborg University) installed on a Samsung Note 
10.1 Tablet (Samsung, Seoul, South Korea) were used. The subjects were instructed to report the 
occurrence and intensity of the aforementioned sensations continuously throughout the 6-minute, 0.2 Hz 
sampling. On the VASs, 0 indicated “no itch” /“no pain”  and 100 indicated “worst imaginable 
itch” /“worst imaginable pain”. The subjects were instructed that itch and pain might, or might not, occur 
following any of the administered provocations and i structed only to rate itching/painful sensations a d 
not innocuous associated sensations such as tingling or warmth. They were also instructed to disregard 
the mild initial pricking pain associated with insertion of spicules and the SPT puncture. From the 
VAS/time data, temporal itch and pain intensity profiles were generated, and mean as well as individual 
peak itch/pain intensity were calculated.  
2.4.3. Assessment of hyperknesis at baseline and after itch provocations: Cutaneous mechanical 
stimuli delivered by a needle or a thin filament typically induces a pricking sensation occasionally 
followed by mild itch both in healthy controls and to a greater extend in chronic itch patients.20,40 
Following an experimental itch provocation, the surro nding skin area becomes increasingly itchy in 
response to this type of mechanical probing 52,78,80. In the present study, sensitivity to mechanically 
evoked itch was tested before and ~12 minutes aftereach itch provocations with 3 von Frey filaments; 
(9.8, 13.7, and 19.6 mN, from North Coast Medical, Gi roy, CA) by stimulating with each filament 2 × 3 
times, for 2-3 seconds, each time instructing the subject to report the resulting itch intensity on a 
numerical rating scale (NRS0-10, with same outer labels as the previously described VAS). The von Frey 
stimuli were delivered immediately next to the site of itch provocation (0.5-2 cm distance) within the 
predefined 4 × 4 cm areas, but never directly within wheal reactions or the area of spicule insertion. 
This technique and the choice of von Frey filaments have previously been described in details.7 Subjects 
were instructed before the onset of data collection that: 1) itch is defined by inducing a desire to scratch 
the probed area and hence this should be the hallmark of their rating, 2) itch may or may not occur in 
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response to the stimuli, and 3) itch could occur during the stimulus itself or immediately after. Non-
uniform terminology is currently being used to describe itch-associated mechanical dysesthesias; 
alloknesis (itch in response to a normally non-itching stimuli) and hyperknesis (increased itch in response 
to a normally itch or pain-evoking stimuli).7,10,30,47,49 Since the presently applied methodology is designed 
to induce mild itch in HC skin and elicits mild itch in majority of HCs prior to itch provocations, we 
apply the term mechanically evoked itch when referring to such data obtained in normal skin of HCs. 
Hyperknesis is used specifically when referring to any observed increase in mechanically evoked itch 
rating, probed as described above. This definition is a line with the originally proposed 
nomenclature.49,50,80. 
 
 
2.5. Inflammation imaging and wheal measurements  
Superficial blood perfusion was assessed at baseline and following the histamine provocation to measure 
the neurogenic inflammatory response. Cowhage produced no discernable flare. The measurements were 
conducted using a MoorFLPI-1 (Moor Instruments Ltd, Axminster, UK) with a 35-cm distance between 
the camera and the skin, exposure time of 8.3 ms, and 160 units of gain. The FLPI data were analyzed 
using MoorFLPI Review V4.0 proprietary software. The induced increases in average and peak 
superficial blood perfusion within the 4 x 4 cm pre-marked areas were used as proxies for inflammation 
intensity. Moreover, the histamine-evoked flare area was calculated as the area of ≥30% perfusion rate 
compared to the surrounding background in accordance with previously described methodology.7,8,65 
Wheal was measured by the longest diagonal and the or ogonal diagonal approximately 15 minutes after 
the histamine pricks were conducted in accordance with standardized recommendation for SPT.35  
 
2.6. Statistics 
Statistical analyses were performed using SPSS (version 23, IBM Corporation, Armonk, NY) and 
GraphPad Prism (version 6.0, La Jolla, CA). Sample siz estimations were based on previous studies and 
test-retest reliability data. The obtained data are presented as arithmetic means ± standard error of the 
mean (SEM), unless otherwise stated. Data were testd for normality using visual inspection and, if 
unclear, the Shapiro-Wilk normality test. Peak and mean of itch/pain were extracted from temporal VAS-
recordings and compared between groups. The primary st tistical analyses for all outcome measures, with
the exception of hyperknesis, MPS, and FLPI (repeated parameters), were performed with independent 
sample t-tests adjusted according to Levene’s variance test and corrected for multiplicity using the Holm-
Sidak approach. For MPS, hyperknesis and FLPI, repeat d measures ANOVAs were constructed with the 
within-subject factors stimulus (MPS; 7 levels, one per stimulator) and time (hyperknesis and FLPI; 2 
levels, before and after itch provocation) and the between-subject factor group (all three outcomes; 2 
levels, AD vs. controls). Mauchly’s test of sphericity was utilized, and in cases where sphericity was 
violated, the Greenhouse-Geisser correction was applied. An unplanned within-subjects analysis (paired t-
test) was conducted specifically for HPT as a difference were evident from the main between-subjects 
comparison. A P-value of ≤ 0.05 was considered significant for all analyses.  
 
3. Results 
 
All subjects in both groups completed all study procedures without the occurrence of immediate or 
delayed adverse reactions or withdrawals. For most parameters, no or very modest, insignificant 
differences were observed within the two HC skin areas, showing limited combined differences 
associated with sensory topography between the investigated sites within the groups. 
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3.1. Severity and characteristics of itch and atopic dermatitis 
The AD patients reported moderate-to-severe daily mean itch (60.7 ± 4.3 VAS0-100) as well as mild-to-
moderate pain (39.7 ± 5.2, VAS0-100) associated with their skin lesions. The itch characteristics, presented 
as medians and quartiles on a Likert Scale0-4, were most consistently described as: “warm” = 3 (3-4), 
“burning” = 3, (3-4), “searing” = 3 (2-4), and “stinging” = 3 (1.25-4). The most prevalent perceived 
aggravating factor was “warmth” (3, 3-4), and “cold” was most consistently described as alleviatory = 3 
(3-4). The most frequent emotional descriptors were: “annoying” = 4 (3.25-4), “bothersome” = 4 (3-4), 
and “my only desire: no itch” = 4 (3-4). Significant sleep interference from itch was reported = 3 (3-4). 
The mean Itch Severity Scale score was 12.5 ± 0.4 (0-21 scale), and the average SCORAD was 35.4 ± 3.1 
(0-103 scale). The most common lesional anatomical area was in and around the flexural area of the 
elbow. Qualitatively, a majority of patients reported that they were under the impression that the 
cutaneous pain occurring on their upper extremity lesions was, mainly or entirely, a self-inflicted 
consequence of scratching.  
 
3.2. Quantitative sensory testing 
 
3.2.1. Thermal detection and pain thresholds: No significant differences or trends were observed with 
regards to any thermal detection or pain thresholds between the AD and control group in lesional or non-
lesional skin areas (see Table 1). In the AD group a within-subjects analysis for HPT in lesional (41.2 ± 
0.8°C vs. non-lesional skin (43.2 ± 0.9°C) demonstrated relative heat hyperalgesia intra-lesionally (P = 
0.009, uncorrected).  
 
3.2.2. Mechanical detection, pain thresholds and mechanical pain sensitivity: Intra-lesionally, the AD 
group exhibited significantly increased MDT compared to the control group, indicative of tactile 
hypoesthesia (Table 1). This difference was not present when comparing non-lesional skin of the AD 
group to corresponding area in HCs. No significant differences were observed for MPT, but a trend 
towards decreased MPT in lesional skin of the AD group was observed (Table 1). No significant 
differences were observed for the wind-up ratio, know  as a perceptual correlate of temporal pain 
summation. Sensitivity to supra-threshold mechanical pain pinprick stimuli was significantly increased in 
both lesional (P < 0.01, group main effect) and non-lesional skin (P < 0.05, group main effect) of the AD 
patients (see Fig. 2A and B). This result indicates m chanical hyperalgesia manifesting to supra-threshold 
stimuli intensities within and beyond the eczematous skin areas.  
 
3.3. Itch provocations  
 
3.3.1. Histamine-induced itch: Histamine-induced mean and peak itch intensities did not differ 
significantly between AD patients and HCs, regardless of whether the provocations were performed in 
lesion or non-lesional skin (Fig. 3A and B). However, a notable trend towards increased itch responses i  
lesional AD skin compared to homologues HC skin wasob erved for both mean and peak itch intensities 
(both: P = 0.07), and these differences were only rendered insignificant when correcting for multiple 
comparisons. The sensitivity to histamine-induced itch n non-lesional skin of AD patients vs. HCs was 
highly similar (P = 0.74 for mean itch, and P = 0.98 for peak itch). Histamine provocations induced mild 
pain in a few individuals, but mean peak pain intensity scores were never >10 (VAS0-100), regardless of 
whether provocations were conducted intra- or extra-lesionally.  
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3.3.2. Cowhage-induced (non-histaminergic) itch: Cowhage-evoked mean and peak itch intensities 
were significantly increased in lesional AD skin vs. corresponding skin in HCs (both: P < 0.01), see Fig. 
3C and D. For instance, the mean itch in response to cowhage was 63% higher in the AD patients (48.3 ± 
3.9, VAS0-100) compared to the HCs (30.4 ± 3.9, VAS0-100). A similar finding was made when comparing 
non-lesional AD skin to corresponding skin in HCs for the mean cowhage-evoked itch (P = 0.03); 
however, here the peak itch intensity difference was not statistically significant (P = 0.087). Temporal 
itch intensity profiles following cowhage provocations are shown in Fig. 3C and 4D. Cowhage induced 
mild pain in a minority of subjects in lesional (peak scores: AD group, 15.1 ± 4.3; HC group, 10.2 ± 2.4), 
and non-lesional skin (peak scores: AD group, 12.3 ± 2.5; HC group, 11.5 ± 3.4), but no significant 
differences were present between groups. 
 
3.3.3. Mechanically evoked itch and hyperknesis: 59.7% of the 300 von Frey triplicate stimulations 
delivered the skin of HCs prior to any itch provocations were rated as itching (≥0.5 on NRS0-10), while the 
equivalent percentage in AD was 73.3% (P < 0.001). Patients with AD exhibited significantly more 
intense itch in response to von Frey stimuli in both lesional and non-lesional skin prior to itch 
provocations (AD group: 2.4 ± 0.3, HC group: 0.9 ± 0.1). Following histamine and cowhage-induced itch 
provocations, both the AD and HC group developed significantly hyperknesis; however, this facilitation 
was more pronounced in the AD group (Fig. 4A and B). AD patients also displayed significant 
hyperknesis in lesional skin following cowhage (4.0 ± 0.4 vs. 2.4 ± 0.3 at baseline, NRS0-10) and 
histamine (4.2 ± 0.5, NRS0-10, both: P < 0.01), and significant increases of less magnitude were also 
observed in corresponding control skin areas in HCs following histamine (1.8 ± 0.3 vs. 0.8 ± 0.1 at 
baseline, NRS0-10, P < 0.01) and cowhage (1.5 ± 0.3 NRS0-10, P < 0.05). Similar but less pronounced 
results were present for extra-lesional skin (Fig. 4B); however, here the histamine provocation did not 
produce significantly more hyperknesis in AD patients compared to HCs. In summary, AD patients 
displayed hyperknesis at baseline, and following itch provocations (both histamine and cowhage intra-
lesionally, and only cowhage extra-lesionally) the AD group developed more pronounced hyperknesis 
than the HCs. 
 
3.4. Neurogenic inflammation and wheal reactions 
No differences were observed for superficial blood perfusion in non-lesional areas at baseline. AD 
patients expectedly had increased blood perfusion levels in lesional skin compared to corresponding 
control areas (P < 0.01), compatible with the observed erythema. Following histamine provocations, both 
HCs and patients with AD exhibited visually perceptible flare reactions immediately surrounding the SPT 
site. Analysis of the FLPI images showed that the flare reactions in non-lesional skin were more 
developed (higher peak intensities and larger areas) in HCs (both: P < 0.05), indicating that this 
neurogenic response pattern might be blunted in AD patients. FLPI analysis of lesional recordings 
following histamine provocations did not reveal group differences of peak perfusion responses. Mean 
perfusion assessment as well as area quantification techniques could not be reliably applied because of 
significant ceiling effects (presumably both physiological and technological) observed in the lesional skin 
of the AD patients (Fig. 5, column a-b, row 4-6). No group differences were found in relation to wheal 
sizes when comparing lesional or non-lesional areas. However, three abnormally large wheals, >40 mm2 
and >5 standard deviations higher than average HC wheals, as well as 4 satellite wheal reactions 
(separately developed wheal reactions several cm away from histamine prick site) were observed in 
lesional skin of the AD patients only.  
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4. Discussion 
 
This study demonstrates for the first time that AD patients with chronic itch exhibit selective intra- and 
extra-lesional hypersensitivity to cowhage provocations (non-histaminergic itch). Moreover, AD patients 
have exaggerated responses (sensitization) to pain-evoking as well as itch-evoking mechanical stimuli 
both intra- and extra-lesionally, indicative of pinrick hyperalgesia and hyperknesis, respectively. 
 
4.1. Itch and pain in atopic dermatitis 
The AD group reported moderate to severe chronic itch with a rated severity equivalent to previous 
studies23,25,64. Notably, 23 of 25 patients reported the presence of pain, and the combined average daily 
pain was 39.7 ± 5.2 (VAS0-100). While the frequency of cutaneous pain in atopic dermatitis has previously 
been investigated (Brenaut et al. (2013) report that ~87% of AD patients experience associated pain18 and 
O’Neill et al. (2011) report a 57.3% prevalence of pain in AD64) the intensity of the pain has, to our 
knowledge, not previously been assessed. It is unclear whether scratching chiefly drives the cutaneous 
pain and/or if it is spontaneously occurring. Given that both histaminergic and non-histaminergic models 
of itch generally produce mild spontaneous pain and hyperalgesia, it is likely that both of these 
mechanisms are involved.10,13,36,52,79 The quality of itch in AD was generally reported as having a warm, 
pricking, searing quality and as being intensified by warmth as well as alleviated by cooling, all of which 
is well aligned with findings from previous studies.23,25,64 While aggravation of itch by warmth is 
speculatively proposed to rely on TRPV1/4-mediated signaling either summating with pruriceptive 
activity at the primary afferent level or convergin onto pruriceptive pathway SDH neurons,3,4 alleviation 
by cooling is likely predominantly mediated by spinal gating of pruriceptive signaling, arising from 
activity of TRPM8-positive cold-receptive Aδ-fibers.11,19,96 An alternative explanation, perhaps 
particularly relevant for warm-induced aggravation f itch, is that simple physical factors such as 
temperature-induced modulation of neuronal membrane pot ntial, channel-kinetics or receptor-agonist 
interactions causes thermally induced itch aggravation/inhibition.21,22,29 Lastly, although sweat has been 
proposed as a potential link between feeling warm and concurrent itch exacerbation, a recent study failed 
to show pruritogenic or itch sensitizing properties of weat.62 
 
4.2. Thermal quantitative sensory testing is normal in AD 
Standardized thermal QSTs yielded mean thresholds cmparable to those found in the normative dataset 
both when conducted intra- and extra-lesionally 65,72,73, however a paired analysis of HPT in lesional vs. 
non-lesional AD skin did indicate mild heat hyperalgesia. One previous study found minor but significant 
impairments in warmth and cold detection thresholds in AD patients, while a similar recent study failed to 
detect significant differences in thermal sensitivity.69 Taken together with the present results, this 
indicates that alterations in thermal detection and pain sensation are likely not a prominent feature in AD 
as is the case, e.g., for certain neuropathic16,56 and musculoskeletal pain etiologies.28,89 Notably, a previous 
study found that noxious suprathreshold heat stimuli evoke itch in AD, conceptually corresponding to 
heat-induced alloknesis.40 This type of sensory assessment is conceivably a more valuable assessment in 
AD patients than standardized thermal QST.  
 
4.3. Intra-lesional hypoesthesia in AD 
The MDT was found to be increased intra- but not extra-lesionally within the AD group. The MDT is a 
perceptual correlate of Aβ-mechanoreceptor function and as such signifies tactile sensitivity.54,72,73 Two 
explanations to the reduced tactile sensitivity are most plausible: 1) prolonged scratching could cause 
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cutaneous nerve fiber density decrease, perhaps affecting mechano-sensitive units,70 2) the finding reflects 
an indirect effect of skin barrier alterations, i.e., lichenification, excoriation and scaling, reducing 
responses to light von Frey stimuli (although attempts were made not to directly stimulate scabbed or 
extensively excoriated, exudative, and lichenificated areas). In either event, evidence suggests that the 
loss of tactile sensitivity might have functional implications in AD. For example, a study found that the
itch-alleviating effect of scratching is blunted in lesional skin of AD patients compared to HCs,42 and 
innocuous mechanical stimulation likely contributes to cratch-mediated itch alleviation.  
 
4.4. Intra- and extra-lesional pinprick hyperalgesia in AD 
The MPT was overall on par with previous studies in HCs.65,72 While insignificant, a trend was observed 
towards reduced MPT in intra-lesional sites compared to homologous sites in HCs, indicative of 
mechanical hyperalgesia. More considerably, MPS was increased, particularly in intra-lesional skin, but 
also to a lesser extent extra-lesionally, when comparing AD patients with the HCs. This sensory 
parameter has not previously been assessed in AD. The mechanism behind hyperalgesia to suprathrehsold 
pinprick also affecting non-lesional skin can only be speculatively accounted for. Conceivable 
mechanisms could involve: 1) peripheral sensitization of mechano-sensitive primary afferents (C- and 
Aδ-fibers), as indicated by increased responses to cowhage provocations. Evidence suggests that AD 
patients have increased circulatory concentrations of everal pro-inflammatory cytokines, chemokines, 
and neurotrophic factors, including, e.g. CCL1, interleukin-2 and NGF.37,63,85,88 In humans, intradermal 
NGF has been experimentally shown to cause both prolonged mechanical hyperalgesia and increased itch 
sensitivity to cowhage in the absence of inflammation.74,75 Hence, increased systemic NGF-levels could 
explain these two findings co-occurring extra-lesionally in AD patients in the present study. Lastly, 
permanent serum concentration changes of chemokines a d cytokine might lead to increased sensitivity 
of peripheral nerves.24,37,58 For instance, CCL1 has been shown to sensitize nociceptors in mice,2 CCL11 
(also increased in serum of AD patients and correlated with severity)44 is up-regulated in rodent models of 
cutaneous hyperalgesia,24 and various chemokines and cytokines are known to be capable of inducing 
long-lasting increases in sensory nerve excitability and conductivity, e.g. by modulation of NaV- and/or 
TRP-channel expression.24,58 However, such mechanisms would have to be relativey selective since, e.g. 
heat pain thresholds and histaminergic itch did not differ significantly between groups, 2) prolonged 
afferent pruriceptive barrage causing a generalized sensitization of mechanoreception, 3) skin barrier 
alterations either associated with AD itself or as  consequence of prolonged usage of topical 
corticosteroids. The additional sensitization observed intra-lesionally is proposed to mechanistically 
resemble the localized hyperalgesia repeatedly shown in HCs immediately following an itch 
provocation.6,52,66,78 Ikoma et al. (2004) also used noxious pin-prick stimuli in AD patients and found 
increased itch responses inside and immediately outside of lesions. However, in this study, the difference 
only manifested in increased ratings of itch (akin to what we observed in response to von Frey filaments 
during the dedicated hyperknesis assessments), while no differences were observed for pain. This 
discrepancy is likely related to the much higher maxi l stimulus intensities used in the present study. 
 
4.5. Increased sensitivity to chemical itch provocations  
In the present study, very similar itch responses wre observed following histamine provocation between 
non-lesional AD and HC skin. This is in line with most previous studies conducting such itch 
provocations, although outlying studies do exist wherein both increased and decreased sensitivity have
been described.5,38,41–43,48,67,91 In lesional AD skin, previous studies have found either no or moderate 
increases in histamine itch responses5,38,41,42,76, in line with the strong trend observed in the present study. 
Hence, while histamine signaling appears to be slightly sensitized in the lesional skin, it is unaltered or 
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even decreased in non-lesional skin. The intra-lesional sensitization to histamine (insignificant when 
multiplicity corrected) coincided with mild heat hyperalgesia. Mechanistically, this suggests that in AD 
kin, modestly sensitized TRPV1-signaling associated with the histaminergic CMi-fiber pathway of itch 
could contribute to augmented itch in response histamine. This could perhaps also explain the intra-
lesional heat-pain evoked itch observed in a previous study in AD patients.40  
 
In contrast to histamine provocations, cowhage provocations have not previously been conducted in 
lesional AD skin. Presently, we show that patients display increased sensitivity to cowhage-induced itch
not only when applied intra-lesionally, but also in extra-lesional skin. The prominent itch responses to 
non-histaminergic chemical pruritic stimulation suggest that pathway-specific itch sensitization may be 
implicated in the sensory symptomatology of AD. Conflicting evidence exists regarding sensitivity to 
cowhage-induced itch in non-lesional AD skin. Papoiu et al. (2011) found no differences between HCs 
and AD patients, but the sample size was modest and he evoked itch was unusually strong in both AD 
and HCs, so a ceiling effect could have been present.67 Oppositely, a recent paper with a larger sample 
size found increased itch in response to cowhage in AD patients akin to the results of the present study 
and suggested that cowhage (and histamine) provocations might have diagnostic value for AD.34 Lastly, a 
study injecting the chemical PAR2-agonist SLIGKV found increased itch responses in patients with AD 
compared to HCs.83 The presence of intra- and extra-lesional hypersensitivity to cowhage-induced, non-
histaminergic itch suggests that new pharmaceuticals targeting PAR2 and, importantly, its downstream 
mediator TRPA1, could be effective antipruritics in AD. Several such drug candidates are currently under 
development.14,95 The findings also lend mechanistic support to the notion that antihistamines are 
ineffective as antipruritics in AD.27,68,90 The blunted flare reactions in non-lesional skin of patients with 
AD following histamine provocations has previously been reported34,41 and could account for the slow 
decline in histaminergic itch observed in AD patients in several studies by hampering local tissue 
clearance of introduced histamine.7,34,41 
 
The present evidence cannot be applied to interpret the relative peripheral vs. central contribution t the 
observed sensitization. However, it is most feasible that the sensitization found to both chemical and
mechanical stimuli in otherwise asymptomatic skin is driven by central mechanisms, while the ‘added’ 
sensitization observed within lesions is likely initiated by peripheral mechanisms associated with ongoing 
inflammation, itch and pain. The increased responses to intra-lesional tests could also be related to a 
stronger localized segmental sensitization (perhaps particularly pertinent for hyperknesis) still mediated 
on a spinal level.  
 
Hyperknesis to von Frey stimuli in AD 
Mechanical pinprick hyperalgesia is pronounced in certain pain populations,56,57 and thus it is pertinent to 
study the parallel phenomenon, hyperknesis, in relation to itch. When stimulating with von Frey filaments 
in a pre-optimized force range7 prior to itch provocations, significantly higher itch ratings were found in 
the AD group intra- and extra-lesionally (Fig. 4). This is aligned with a previous study in AD patients 
using custom-made weighted needles to conduct a similar assessment40 as well as case reports in 
neuropathic itch patients.12 This mechanically evoked itch hypersensitivity was aggravated following 
subsequent itch provocations, most prominently in lesional skin, but also in non-lesional skin, where 
cowhage elicited significantly stronger hyperknesis in AD patients compared with the HC group. It is 
unclear which neuronal structures convey mechanically evoked itch. Selective tactile C-fibers have been 
proposed,30 but Aδ- and PmC-fibers seem to be more probable candidates: th  Aδ-nociceptors because of 
their involvement in pinprick hyperalgesia100 and the PmC-fibers because of the delayed onset of itch 
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following mechanical stimuli.40 It is likely that increased responsiveness to mechanical itch stimuli 
involves a C-fiber mediated sensitization of central pruriceptive neurons, which then in turn receive 
convergent input from relevant mechano-sensitive units, thus mediating an augmented sense of 
mechanically evoked itch akin to the mechanism involved in pinprick hyperalgesia.49,81 
 
Assessment of mechanical pain hypersensitivity has been widely utilized in clinical pain research and 
therapy as a tool to assess potential sensitization, and recent studies indicate that it could be a valuable 
guide and predictor of therapeutic responsiveness to analgesic drugs.16,26,56,57,72 The clinical utility of 
assessment of hyperknesis and alloknesis as well as itch sensitization in general (e.g., sensitization t  
chemical provocations) remains to be explored. Clearly, ntipruritic therapeutic measures should focus on 
reducing local inflammation and targeting the underlying cause. However, tentatively, AD patients 
displaying no signs of sensitization might respond favorably to peripherally acting anti-inflammatory and 
immune-modulatory drugs, while patients exhibiting si nificant itch sensitization may benefit more from 
antipruritic therapy that also inhibits central processing of itch. 
 
Because pruriceptive afferents generally also responds to application of algogens (causing pain) and as 
such are nociceptors, a theory has recently been proposed that neuronal encoding of itch may rely on a 
high spatial contrast from afferent input. That is, if a few cutaneous nociceptors are activated while 
neighboring units remain silent, itch is perceived, while more uniform nociceptive activation causes pain 
perception51,60,61,78 (the spinal or supra-spinal filtering mechanism for such encoding is unknown). The 
combined findings of intra-lesional decreased tactile sensitivity increased MPS, increased itch in respon e 
to cowhage and von Frey stimuli could perhaps be int rpreted in the light of this theory. I.e. increasd 
MDT suggests fiber denervation (aligned with studies showing decreased intra-epidermal density in AD 
skin70) this could facilitate increased spatial contrast from the cowhage provocations and von Frey itch 
probing. Since increased mechanical pain sensitivity was also observed these findings could collectively 
be interpreted as a combination of activation of fewer nociceptive endings concurrently with stronger 
activation of the remaining endings due to sensitizat on. 
 
Conclusion 
In summary, AD patients display aberrant somatosensory sensitivity to distinct chemical and mechanical 
stimuli. This enhanced sensitivity is not restricted o the lesional skin areas and thus presumably involves 
both centrally and peripherally mediated sensitizaton mechanisms. Investigated for the first time, marked 
intra- as well as extra-lesional hypersensitivity to cowhage-induced non-histaminergic itch was shown. 
Moreover, increased sensitivity to pain- and itch-evoking mechanical stimuli, but not to histamine-
induced itch, was found. This suggests the importance of PAR2-positive PmC-nociceptors in initiating 
and maintaining chronic itch in AD and highlights this pathway as a potential future therapeutic targe.  
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Figure and table legends 
 
Figure 1. Flowchart of experimental protocol. A total of four itch provocations were conducted (two in lesional and 
two in non-lesional skin) in a randomized order, with provocations always alternating between the two areas. The 
order presented in the picture represents an example (greyed out provocations not conducted). The entire 
experimental session lasted approximately 3 hours. Abbreviations: AD = Atopic Dermatitis; CDT = Cold Detection 
Threshold; CPT = Cold Pain Threshold; eVAS = Electronic Visual Analog Scale; FLPI = Full-Field Laser Perfusion 
Imaging; MPT = Mechanical Pain Threshold; MPS = Mechanical Pain Sensitivity; NRS = Numerical Rating Scale; 
HPT = Heat Pain Threshold; WDT = Warmth Detection Threshold; WUR = Wind-Up Ratio.  
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Figure 2A and B. Mechanical pain sensitivity (MPS) in lesional (A) and non-lesional skin (B) of AD patients (red) 
and corresponding sites in healthy controls (blue). Asterisks to the left of the stimulus response curves indicates a 
significant group main effect (scores of entire stimuli series), while asterisks immediately above data points 
indicates post hoc group differences (group x stimulus interaction) for ratings produced by each of the pinprick 
stimulators. Abbreviations: AD = Atopic Dermatitis; HC = Healthy Control. Significance indicators: * = P ≤ 0.05, 
** = P ≤ 0.01. 
 
Figure 3A-D. Temporal profiles of itch intensity elicited by histamine (A and B) and cowhage provocations (C and 
D) in lesional (A) and non-lesional skin (B) as well as in respective control sites (C and D). Rating frequency was 
down sampled from 1/5 sec (0.2 Hz) to 1/15 sec (0.067 hz) by averaging 3 consecutive ratings for improved 
overview. Note that while histamine-induced itch was not significantly increased in lesional AD skin (A), a 
considerable tendency was observed (P = 0.07). Statistical results were based on mean score  for the 0-6 min period. 
Abbreviations: AD = Atopic Dermatitis; HC = Healthy Control. * = P ≤ 0.05, ** = P ≤ 0.01. 
 
Figure 4A and B. Mechanically evoked itch in lesional (A) and non-lesional skin (B) of AD patients (red) and 
corresponding sites in healthy control (blue). The sensitivity to mechanically evoked itch was assessed at baseline as 
well as following histamine and cowhage provocations. Abbreviations: AD = Atopic Dermatitis, HC = Healthy 
Control. * = P ≤ 0.05, ** = P ≤ 0.01. 
 
Figure 5. A representative series of Full-Field Laser Perfusion (FLPI) images recorded at baseline (column a and b) 
and following histamine provocations (column c and d), signifying “endogenous” skin inflammation in atopic 
dermatitis and the neurogenic inflammation evoked by histamine in both groups. Images in row no. 1 through 3 are 
from non-lesional skin areas and corresponding control areas, while images in row no. 4 through 6 are recorded in 
lesional skin areas and corresponding control areas. Column a, row no. 4 (dorsal wrist/hand), 5 (lateral aspect of 
elbow crease) and 6 (medial aspect of elbow crease), show typical FLPI images of atopic dermatitis lesions. Note: 1) 
the light speckled inflammation pattern (e.g., column a, row no. 1 and 2), recognizable with FLPI, often observed in 
AD even in skin that appears normal by visual inspection; 2) the blunted flare response to histamine observable in 
non-lesional skin of AD patients (compare column b, row no. 1-3 to column d, row no. 1-3), particularly clear when 
measuring the intensity of blood flow immediately next to the skin prick test site; 3) that when comparing it is 
difficult to gauge the inflammatory response evoked by histamine. Abbreviations: Arb = Arbitrary.  
 
Table 1. Results from the quantitative sensory testing in lesional as well as non-lesional skin and statistical 
outcomes. Abbreviations: AD = Atopic Dermatitis; CDT = Cold Detection Threshold; CPT = Cold Pain Thresold; 
MDT = Mechanical Detection Threshold; mN = miliNewton, MPT = Mechanical Pain Threshold; HC = Healthy 
Control; HPT = Heat Pain Threshold; WDT = Warmth Detection Threshold; WUR = Wind-Up Ratio. * = P ≤ 0.05, § 
= insignificant trend. 
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Table 1 
 
Lesional skin Non-lesional skin QST 
parameter AD HC P-value AD HC P-value 
CDT (°C) 30.0 ± 0.2 30.4 ± 0.2 P = 0.16 29.9 ± 0.3 30.2 ± 0.2 P = 0.40 
WDT (°C) 34.0 ± 0.4 34.1 ± 0.1 P = 0.73 34.9 ± 0.3 34.8 ± 0.2 P = 0.76 
CPT (°C) 18.5 ± 1.8 17.3 ± 1.4 P = 0.61 16.0 ± 1.8 17.4 ± 1.3 P = 0.56 
HPT (°C) 41.2 ± 0.8 41.9 ± 0.6 P = 0.51 43.2 ± 0.9 41.4 ± 0.6 P = 0.10 
MDT (mN) 3.4 ± 0.1 3.1 ± 0.1 P = 0.049* 3.2 ± 0.8 3.2 ± 0.7 P = 0.66 
MPT (mN) 133.0 ± 19.6 182.3 ± 21.3 P = 0.09§ 188.5 ± 24.3 185.2 ± 18.5 P = 0.92 
WUR (ratio) 1.9 ± 0.14 2.1 ± 0.19 P = 0.38 1.8 ± 0.14 2.1 ± 0.17 P = 0.30 
 
AC
CE
PT
ED
Copyright  2017 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
Figure 1
Copyright  2017 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
Figure 2
Copyright  2017 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
Figure 3_revised
Copyright  2017 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
Figure 4
Copyright  2017 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
Figure 5_revised
Copyright  2017 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
